The Experts below are selected from a list of 21387 Experts worldwide ranked by ideXlab platform

Yaddanapudi Ravindranath - One of the best experts on this subject based on the ideXlab platform.

Michael E. Trigg - One of the best experts on this subject based on the ideXlab platform.

Susana C Raimondi - One of the best experts on this subject based on the ideXlab platform.

  • Prognostic features in acute megakaryoblastic Leukemia in Children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421.
    Leukemia, 2012
    Co-Authors: Maureen M. O'brien, Susana C Raimondi, Xueyuan Cao, Stanley Pounds, Gary V. Dahl, Norman J. Lacayo, Jeffrey W. Taub, Myron Chang, Howard J. Weinstein, Yaddanapudi Ravindranath
    Abstract:

    Prognostic features in acute megakaryoblastic Leukemia in Children without Down syndrome: a report from the AML02 multicenter trial and the Children’s Oncology Group Study POG 9421

  • Acute mixed lineage Leukemia in Children: the experience of St Jude Children's Research Hospital
    Blood, 2009
    Co-Authors: Jeffrey E. Rubnitz, Frederick G Behm, Susana C Raimondi, Xueyuan Cao, Stanley Pounds, Mihaela Onciu, Sheila A. Shurtleff, Dario Campana, Bassem I. Razzouk, Raul C Ribeiro
    Abstract:

    To characterize the biology and optimal therapy of acute mixed-lineage Leukemia in Children, we reviewed the pathologic and clinical features, including response to therapy, of 35 patients with mixed-lineage Leukemia. The majority of cases (91%) had blasts cells that simultaneously expressed either T-lineage plus myeloid markers (T/myeloid, n = 20) or B-lineage plus myeloid markers (B/myeloid, n = 12). Overall survival rates for the B/myeloid and T/myeloid subgroups were not significantly different from each other or from the rate for acute myeloid Leukemia (AML) but were inferior to the outcome in Children with acute lymphoblastic Leukemia (ALL). Patients who failed to achieve complete remission with AML-directed therapy could often be induced with a regimen of prednisone, vincristine, and L-asparaginase. Analysis of gene-expression patterns identified a subset of biphenotypic Leukemias that did not cluster with T-cell ALL, B-progenitor ALL, or AML. We propose that treatment for biphenotypic Leukemia begin with one course of AML-type induction therapy, with a provision for a switch to lymphoid-type induction therapy with a glucocorticoid, vincristine, and L-asparaginase if the patient responds poorly. We also suggest that hematopoietic stem cell transplantation is often not required for cure of these patients.

  • Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia
    The New England Journal of Medicine, 1991
    Co-Authors: Raul C Ribeiro, M. Hazem Mahmoud, Michael L Hancock, David R Head, Gaston K Rivera, Frederick G Behm, Susana C Raimondi, William E Evans, John T. Sandlund
    Abstract:

    Abstract Background and Methods. Treatment of cancer with the epipodophyllotoxins (etoposide and teniposide) has been linked to the development of acute myeloid Leukemia (AML) in Children and adults, but the factors that might influence the risk of this complication of therapy are poorly defined. We therefore assessed the importance of potential risk factors for secondary AML in 734 consecutive Children with acute lymphoblastic Leukemia who attained complete remission and received continuation (maintenance) treatment according to different schedules of epipodophyllotoxin administration. Results. Secondary AML was diagnosed in 21 of the 734 patients, in 17 of whom this complication was the initial adverse event. Prolonged administration of epipodophyllotoxin (teniposide with or without etoposide) twice weekly or weekly was independently associated with the development of secondary AML (P

  • acute myeloid Leukemia in Children treated with epipodophyllotoxins for acute lymphoblastic Leukemia
    The New England Journal of Medicine, 1991
    Co-Authors: Chinghon Pui, Michael L Hancock, David R Head, Gaston K Rivera, Frederick G Behm, Susana C Raimondi, Raul C Ribeiro, William E Evans, Hazem M Mahmoud, John T. Sandlund
    Abstract:

    Abstract Background and Methods. Treatment of cancer with the epipodophyllotoxins (etoposide and teniposide) has been linked to the development of acute myeloid Leukemia (AML) in Children and adults, but the factors that might influence the risk of this complication of therapy are poorly defined. We therefore assessed the importance of potential risk factors for secondary AML in 734 consecutive Children with acute lymphoblastic Leukemia who attained complete remission and received continuation (maintenance) treatment according to different schedules of epipodophyllotoxin administration. Results. Secondary AML was diagnosed in 21 of the 734 patients, in 17 of whom this complication was the initial adverse event. Prolonged administration of epipodophyllotoxin (teniposide with or without etoposide) twice weekly or weekly was independently associated with the development of secondary AML (P<0.01 by Cox regression analysis). The overall cumulative risk of AML at six years was 3.8 percent (95 percent confidence...

Adrianne K. Holmes - One of the best experts on this subject based on the ideXlab platform.

  • Risk Factors for Acute Leukemia in Children: A Review
    Environmental health perspectives, 2007
    Co-Authors: Martin Belson, Beverely Kingsley, Adrianne K. Holmes
    Abstract:

    Although overall incidence is rare, Leukemia is the most common type of childhood cancer. It accounts for 30% of all cancers diagnosed in Children younger than 15 years. Within this population, acute lymphocytic Leukemia (ALL) occurs approximately five times more frequently than acute myelogenous Leukemia (AML) and accounts for approximately 78% of all childhood Leukemia diagnoses. Epidemiologic studies of acute Leukemias in Children have examined possible risk factors, including genetic, infectious, and environmental, in an attempt to determine etiology. Only one environmental risk factor (ionizing radiation) has been significantly linked to ALL or AML. Most environmental risk factors have been found to be weakly and inconsistently associated with either form of acute childhood Leukemia. Our review focuses on the demographics of childhood Leukemia and the risk factors that have been associated with the development of childhood ALL or AML. The environmental risk factors discussed include ionizing radiation, non-ionizing radiation, hydrocarbons, pesticides, alcohol use, cigarette smoking, and illicit drug use. Knowledge of these particular risk factors can be used to support measures to reduce potentially harmful exposures and decrease the risk of disease. We also review genetic and infectious risk factors and other variables, including maternal reproductive history and birth characteristics.

Juan Manuel Mejía-aranguré - One of the best experts on this subject based on the ideXlab platform.

  • Acute Leukemia in Children.
    BioMed research international, 2015
    Co-Authors: Juan Manuel Mejía-aranguré, Richard J. Q. Mcnally
    Abstract:

    Acute lymphoblastic Leukemia (ALL) is the most common cancer during childhood. Nevertheless, in recent years there have been marked improvements in treatment and consequent survival. There are a number of patients that experience relapses and patients that cannot be cured. in this special issue different aspects relating to factors influencing the best response to treatment are described. M. Czogala et al. showed that plasma ammonia concentration reflexes L-asparaginase activity may be a useful tool for assessing treatment in Children with ALL. in another study A. Medina-Sanson et al. identified the importance of a genetic polymorphism of deoxycytidine kinase and cytidine deaminase in assessing the toxicity by cytarabine in Children with acute myeloid Leukemia and found that this polymorphism might predict death in affected Children. A. Vilchis-Ordonez et al. addressed a very interesting topic about subpopulations of leukemic cells that contribute to a proinflammatory microenvironment within B-ALL bone marrow that may cause a delay in the normal hematopoiesis. Two studies assessed the participation of environmental risk factors in the development of acute Leukemia. A. Morales-Sanchez et al. did not find that EBV, HCMV, HHV6, and HHV7 were related to the development of ALL. Furthermore, J. D. Ferreira et al. did not show that maternal alcohol consumption during pregnancy was associated with Leukemia in young Children. Finally a study by V. C. Bekker-Mendez et al. demonstrated differences in the frequency of gene rearrangement between the Mexican population and populations from developed countries. From these articles it is clear that throughout the world the survival of Children with acute Leukemia is a great concern, especially in less developed countries. It is very important to search for factors associated with treatment compliance in Children and those factors that may be related to treatment response. The microenvironment in the leukemic bone marrow is a very important factor in the etiology of acute Leukemia. Recovery of the bone marrow during treatment is also very important and further studies are needed to address this important aspect. The environmental etiology of acute Leukemia is a challenge that still has not been resolved. To identify environmental risk factors is not easy. It is important to identify both the environmental risk factors and also the gene-environment interactions that increase the susceptibility to development of Leukemia. The presentation of acute kinds of Leukemia in Hispanic Children is different from other populations; notably clinical features, the age incidence peak, and molecular factors are different. in this special issue the complexity of the molecular and clinical epidemiology of acute Leukemia in Children has been shown. There are countries where success has been clearly demonstrated, but in other countries this is not apparent. This disease kills more Children in developed countries and some emerging economies. There is a need to strengthen the research groups that are working to identify the factors that affect the adherence to treatment and the response to treatment. However, there is also a need for integration with those research groups that are working on the etiology of Leukemia, especially including epidemiology and cellular and molecular biology. We need to understand more about Leukemia, in order to be able to cure and prevent it. The challenge continues because it is not a dream to think that one day almost all kinds of Leukemia in Children could be cured and that one day this disease could be prevented. Juan Manuel Mejia-Arangure Richard J. Q. McNally

  • inTERACTION BETWEEN THE SUSCEPTIBILITY TO DEVELOP ACUTE Leukemia in Children AND PATERNAL SMOKinG
    ISEE Conference Abstracts, 2011
    Co-Authors: Juan Manuel Mejía-aranguré, María Luisa Pérez-saldivar, Janet Flores, Roberto Bernáldez, María De Los A Del Campo, Aurora Medina, Miguel A Palomo, Rogelio Paredes, Armando Martínez, Ma Carmen Rodriguez
    Abstract:

    Background and Aims. It has been suggested that acute Leukemia (AL) can be the result of the interaction between inherited susceptibility to the disease and exposure to different carcinogenic facto...

  • Magnetic fields and acute Leukemia in Children with Down syndrome.
    Epidemiology (Cambridge Mass.), 2007
    Co-Authors: Juan Manuel Mejía-aranguré, Arturo Fajardo-gutiérrez, Fabio Salamanca-gómez, Armando Martínez-avalos, María Luisa Pérez-saldivar, Clara Gorodezky, Lina Romero-guzman, Maria De Los Angeles Del Campo-martinez, Janet Flores-lujano, Leora Velasquez-perez
    Abstract:

    Background:We analyzed effects of exposure to magnetic fields on the expression of acute Leukemia in Children with Down syndrome (who have a 20-fold higher risk of Leukemia).Methods:We performed a case–control study that included 42 Children with both acute Leukemia and Down syndrome as cases and 12

  • Environmental factors contributing to the development of childhood Leukemia in Children with Down's syndrome.
    Leukemia, 2003
    Co-Authors: Juan Manuel Mejía-aranguré, Arturo Fajardo-gutiérrez, H Flores-aguilar, Fabio Salamanca-gómez, Virginia Palma-padilla, Rogelio Paredes-aguilera, Roberto Bernáldez-ríos, A Ortiz-fernandez, Armando Martínez-avalos
    Abstract:

    Environmental factors contributing to the development of childhood Leukemia in Children with Down's syndrome